beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging 25

Not yet recruiting
Clinical Trial NCT07216352 is an interventional study for Laxity; Skin and is currently not yet recruiting. Enrollment is planned to begin on October 25, 2025 and continue until the study accrues 25 participants. Led by Goldman, Butterwick, Fitzpatrick and Groff, this study is expected to complete by May 30, 2026. The latest data from ClinicalTrials.gov was last updated on October 28, 2025.
Brief Summary
The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be conducted in non-menopausal female and male subjects who are on glucagon-like peptide-1 (GLP-1) agonist therapy for weight loss.
Detailed Description
enrolled subjects will apply a topical serum (AGE Serum) to the full face and neck twice daily for 12 weeks. Subject follow-up visits will occur at Week 6 and Week 12. Subjects will complete assessments and participate in and standardized 2D and 3D (Visia) digital photography.
Official Title

Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Non-menopausal Patients on Glucagon-like Peptide-1 Agonists

Conditions
Laxity; Skin
Other Study IDs
  • AGE-SERUM-2025
NCT ID Number
NCT07216352
Start Date (Actual)
2025-10-25
Last Update Posted
2025-10-28
Completion Date (Estimated)
2026-05-30
Enrollment (Estimated)
25
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
glp1
weight loss
skin laxity
skin texture
skin tone
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalAGE Product
Enrolled subjects will received AGE Serum.
AGE Serum
AGE serum is a topical that contains a high concentration of 30% Proxylane and a synergistic blend of fruit-derived flavonoids (blueberry, pomegranate) and Cassia alata extract.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Modified Griffith Scale
Modified Griffiths 10-point scale to be used for investigator grading of cutaneous signs of photoaging on the face. Global Fine Lines. Scale 0 (no fine lines) to 9 (numerous, many fine lines) Overall Hyperpigmentation: Scale 0 (no hyperpigmentation) to 9 (significant hyperpigmentation) Skin Tone Eveness: Scale 0 (very even tone) to 9 (uneven, discolored appearance) Skin Elasticity: Score 0 (skin feels toned and dense) to 9 (skin feels thin and flabby) Skin Firmness: Score 0 (firm, tight feeling) to 9 (loose, lax feeling) Skin Radiance: Score 0 (very radiant, luminous, glowing) to 9 (very dull) Skin Texture: Score 0 (very smooth) to 9 (very rough)
Baseline, Week 6 and Week12
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Physician Global Aesthetic Improvement Scale
Physician Grading: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
Week 12
Subject Global Aesthetic Improvement Scale
Subject Grading: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
Week 12
Subject Self-Assessment Questionnaire
Circle One Skin Feels More Comfortable: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Appears Younger Looking: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Appears Healthier: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Looks Renewed/Revitalized: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Looks Firmer: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Skin Feels Elastic : Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly Redness Looks Reduced: Agree Strongly Agree Neither Agree Disagree Disagree Disagree Strongly
Baseline, Week 6 and Week 12
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
25 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  1. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
  2. Adult men and women aged 25-50 years.
  3. Fitzpatrick skin types I-IV.
  4. Current treatment with a stable dose of GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least last 6 months.
  5. Must be willing to sign a photography release and ICF, and complete the entire course of the study.
  6. Subjects in good general health based on the investigator's judgment and medical history.
  7. Negative urine pregnancy test result at the time of study entry (if applicable).
  8. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.

A. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device/coil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and/or vasectomized partners must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.

B. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and/or both ovaries (oophorectomy), or bilateral tubal ligation.

  1. Pregnancy or planned pregnancy during the study or currently breastfeeding.
  2. Current menopausal state.
  3. Any uncontrolled systemic disease.
  4. Current use of other GLP-1 agonist therapy aside from the GLP-1 agonist class of medications (Ozempic, Rybelsus, or Wegovy).
  5. History of autoimmune connective tissue disease.
  6. Current use of immunosuppressive medication.
  7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  8. Active dermatitis or active infection in the proposed treatment area.
  9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
  10. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment.
  11. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.
  12. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.
  13. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding.
  14. Inability to ambulate following the procedure.
  15. History of lidocaine and/or epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.
  16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
  17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Goldman, Butterwick, Fitzpatrick and Groff logoGoldman, Butterwick, Fitzpatrick and Groff
L'Oreal logoL'Oreal
Study Central Contact
Contact: Andrea Paccheco, 858-657-1004, [email protected]
1 Study Locations in 1 Countries

California

West Dermatology Research Center, San Diego, California, 92121, United States
Andrea Pacheco, Contact, 858-657-1004, [email protected]
Freia Canals-Cistero, Contact, 858-657-1004